Surgery is still considered to be the mainstay for the treatment of localized gastric cancer with negative margins (R0-resection) and an adequate lymph-node-dissection (D2-lymphadenectomy). Unfortunately, most cases of gastric cancer are only diagnosed at an advanced stage due to frequent recurrences after primary resection in curative intent. In order to improve prognosis after curative resection, in the recent past, patients with locally advanced tumors were subjected to a pre-, peri-, or postoperative treatment. Interestingly, postoperative chemotherapy has significantly improved survival after gastric resection in Asia, adjuvant radiochemotherapy is favored in North America and perioperative chemotherapy is considered as a treatment of choice in Europe indicating region specific approach towards the treatment. Recently there has also been growing evidence of positive outcomes of neoadjuvant radiochemotherapy on patient survival. In the present article, we discuss the concepts of neoadjuvant treatment approach and provide recommendations to surgeons based on current evidence. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
In comparison to most Asian countries (Korea, Japan, Taiwan), Western countries lack national screening programs, since those are not considered rational given the much lower gastric cancer incidence compared to Asia. 1 Therefore gastric cancer is usually diagnosed at an advanced stage in the West due to mostly unspecific symptoms. 2 This is why its prognosis is still bad in spite of adequate surgery with radical lymphadenectomy. While the 5-year survival of patients with early gastric cancer is about 75%, 3 it is 30%
or less for patients with extensive lymph node involvement. 2 Since the early 90s of the last century neoadjuvant treatment concepts are increasingly employed in the treatment of locally advanced gastric cancer, especially in Europe. Hereby phase II studies consistently demonstrated positive effects of preoperative chemotherapy (high R0 resection-rates and good survival-rates). 4, 5 Meanwhile two randomized studies were able to demonstrate the advantage of perioperative chemotherapy (pre-and postoperative) over surgery only. 6, 7 Regarding the effects on the tumor tissue but due to the small number of patients not significant in terms of a survival difference, this could also be shown by another randomized trial for preoperative chemotherapy only. 8 
Neoadjuvant/Perioperative Chemotherapy
The advocates of neoadjuvant chemotherapy in the sense of the meaning, which means preoperative chemotherapy only, invoke certain advantages in comparison to the adjuvant, postoperative can assumed that all those points were evenly distributed among both treatment arms, the results of these two studies are generally accepted in the Western hemisphere, which presently makes perioperative chemotherapy the standard treatment in Europe.
In 1999 the EORTC 40954-trial 8 was issued with the goal to achieve a higher surgical quality and higher grade of standardization in comparison to the trials mentioned before. In this trial preoperative chemotherapy only with cisplatin, 5-FU and folinic acid (PLF-protocol) was employed in a phase III setting. Only patients with locally advanced, resectable gastric cancer or adenocarcinoma of the EGJ (adenocarcinoma of the esophagogastric junction [AEG] II and III) were included. All patients were subjected to an elaborate staging workup with esophagogastroduodenoscopy (EGD), endoscopic ultrasound (EUS), computed tomography (CT) and a standardized staging-laparoscopy. 14 Resection was performed obeying strict surgical quality standards, including a D2-lymphadenectomy.
Regrettably the trial had to be closed early due to poor accrual after Regrettably the trial did not meet its accrual goals and was closed CT = chemotherapy; CRT = chemoradiotherapy; GC = gastric cancer; EGJ = esophagogastric junction; res. = surgery only; mult. = multimodal therapy; OS = overall survival; PFS = progression free survival; DFS = disease-free survival. *As determined by the surgeon, † also included 23% of esophageal squamous cell carcinoma in each arm. were similar in both arms. Even though the benefit of neoadjuvant CRT on survival was consistent across all subgroups analyzed, it was most pronounced in the subgroup of patients with squamouscell carcinoma. Table 1 gives an overview on the relevant randomized trials investigating neoadjuvant therapy in locally advanced gastric cancer.
Conclusions
Interestingly different approaches in multimodal gastric cancer therapy can be observed in Asia and Europe: while Asian countries [22] [23] [24] in Asian countries where gastric carcinoma in the proper sense is more common junctional adenocarcinomas are still rare. 25, 26 There is evidence from a metaanalysis and a retrospective analysis of a large single-center cohort, that predominantly patients with cancer of the EGJ seem to benefit from neoadjuvant chemotherapy. 16, 27 Also both landmark trials showing a positive effect of neoadjuvant CRT just included adenocarcinomas of the EGJ. It is questionable, however, given the accrual problems of previous trials 8, 9 if such trials are presently feasible in Europe.
